• Platelet transfusions can have limited efficacy during hemorrhage associated with coagulopathy.
Essentials
• Platelet transfusions can have limited efficacy during hemorrhage associated with coagulopathy.
• Thrombin can be shielded by encapsulation into nanoliposomes and delivered to platelets ex vivo.
• Loading platelets with liposomal thrombin improved several aspects of platelet coagulability.
• Platelets loaded with liposomal thrombin can overcome some coagulopathic deficiencies in vitro.
Summary. Background: Platelets are integral to clot formation and are often transfused to stop or prevent bleeding. However, transfusions of platelets are not always effective, particularly in the most severe cases of hemorrhage. Nanoparticle systems have been developed to mimic platelets but inherently lack important aspects of platelet function, which limits their potential effectiveness. Objectives: Increasing the natural coagulability of transfusable platelets could increase their efficacy during treatment of severe hemorrhage. Thrombin is a potent platelet agonist that currently cannot be used intravenously because of the risk of thrombosis. We hypothesized that delivery of thrombin to ex vivo platelets via liposomal encapsulation would enable transfusable platelets to become more coagulable in response to platelet agonists. Methods: Thrombin was encapsulated into nanoliposomes and delivered to platelets ex vivo. Platelet coagulability was measured by monitoring platelet activation, clot contraction, clot time and clot stability in several in vitro assays. These parameters were also measured
Introduction
Platelets naturally detect damaged vasculature, where they become activated to form a platelet plug and help initiate coagulation to stop bleeding [1] . Platelet transfusions are used clinically to reduce bleeding, but transfusions of these and other blood components are not always effective during severe hemorrhage [2, 3] . A major component of coagulopathy is platelet dysfunction, where platelets no longer respond to agonists such as ADP and collagen, and platelet dysfunction is strongly correlated with mortality during traumatic bleeding [4] [5] [6] . Several approaches are being developed to enhance or replace platelet transfusions. These include using coldstored platelets, lyophilized platelets and modified platelets, as well as artificial platelets. In particular, several promising nanoparticle-based systems of artificial platelets, or platelet mimics, have been developed to augment or replace platelet transfusions in acute severe bleeding [7] [8] [9] [10] . Although these systems have the advantage of long shelf lives and low immunogenicity, they cannot adequately mimic all the important and diverse aspects of platelet structure and function on a single platform, including the ability to deliver a wide range of biomolecules that collectively contribute to clot formation, stabilization and contraction, and longer-term wound healing [10] [11] [12] [13] . Alternatively, developing a strategy that improves the natural function of transfused platelets, specifically during platelet activation, would be an important step towards increasing the efficacy of platelet transfusions during severe bleeding.
Platelets are modifiable and have been engineered to have enhanced hemostatic function through genetic modification of megakaryocytes [14, 15] . These studies demonstrated that enhancing platelet coagulability could improve overall hemostasis in vivo; however, clinical use of this technology would currently require bone marrow transplantation, which is not appropriate for cases of acute hemorrhage. Previously, we have modified platelet function by loading platelets with transcriptional machinery, allowing anucleate platelets to transcribe exogenous RNA [16] . This was achieved by encapsulating several biomolecules into liposomes, including a functional enzyme. Nanoparticles have been used extensively to encapsulate enzymes and shield their enzymatic activity until they are delivered to the intended cells or sites of action, where the enzymes can be released into the cytoplasm of the cell or extracellularly [17] [18] [19] . Thrombin, a potent hemostatic enzyme and platelet agonist, has also been encapsulated into polymeric and aptamer-based nanoparticles for controlled local delivery and release [20, 21] . Currently, thrombin is only approved for topical administration because high concentrations of active thrombin in circulation cause systemic thrombosis [22] . Thus, we hypothesized that thrombin can be encapsulated into nanoliposomes and be internalized by platelets ex vivo in order to be temporarily shielded, resulting in enhanced platelet coagulability during platelet activation.
Materials and methods

Isolating platelets
Approvals for the study were given by the research ethics boards of the University of British Columbia. Informed signed consent was obtained from healthy volunteers prior to collecting whole blood from donors. Whole blood was collected into tubes containing sodium citrate (105 mM). Platelets were isolated from citrated whole blood by centrifuging at 100 9 g for 20 min and collecting the platelet-rich plasma (PRP), which was the top 75% (v/v) of the upper layer. To obtain platelet-poor plasma (PPP), the remaining whole blood was centrifuged at 1000 9 g for 10 min. To obtain purified platelets, PRP was centrifuged at 250 9 g for 20 min and the plasma was removed. The platelets were washed once in a buffer containing citrate and glucose (CGS; 120 mM NaCl, 30 mM D-glucose, 11 mM trisodium citrate, pH 6.5) and once in Tyrode's-HEPES buffer (1.8 mM CaCl 2 , 1.1 mM MgCl 2 , 2.7 mM KCl, 137 mM NaCl, 0.4 mM NaH 2 PO 4 , 10 mM HEPES, 5.6 mM D-glucose, pH 6.5) at 250 9 g for 10 min. Washed platelets were resuspended in Tyrode's-HEPES at a final concentration of 200 9 10 9 platelets L À1 .
For trauma patient samples, human subjects (≥ 18 years of age) who were not pregnant or incarcerated, presented directly from the place of injury and received fewer than three units of transfused blood products, were enrolled as part of a single-center observational study taking place at the Harborview Medical Center Emergency Department (ED) in Seattle, WA, USA. Delayed written consent was obtained for study participation from all study subjects in accordance with the Declaration of Helsinki in a protocol approved by the University of Washington Institutional Review Board. Blood was collected from a peripheral intravenous line on arrival at the Emergency Department and 0.6 mL of plasma was stored at À80°C until used for this study.
Preparing and characterizing liposomal thrombin
Washed platelets were loaded with liposomes as previously described, with minor modifications [16] . Briefly, 4.3 lM of human alpha thrombin or DFP active site blocked human alpha thrombin (Haematologic Technologies Inc. Essex Junction, VT, USA) in Tris-buffered saline (TBS) was added to a 5-mg lipid film, consisting of 1,2-dioleoyl-sn-glycero-3-phosphocholine:cholesterol:1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPC:chol: DOPE; 23:23:4; Avanti Polar Lipids, Alabaster, AL, USA, cholesterol from Sigma, Oakville, Canada), and extruded five times through a 200-nm filter using a LIPEX extruder (Northern Lipids Inc., Burnaby, Canada). Liposomes were then passed through a cationic exchange column (Vivapure S Mini H, Sartorius, G€ ottingen, Germany) to remove unencapsulated thrombin. Efficient removal of unencapsulated thrombin was confirmed by measuring thrombin activity of the column eluate using a fluorogenic substrate (Boc-Asp(OBzl)-ProArg-MCA; Peptide Institute Inc. Osaka, Japan), and incubating the column eluate with platelets (1:20 v/v) to determine platelet activation by monitoring CD62P expression using flow cytometry. Fibrin formation time in PPP following incubation with purified liposomal thrombin (1:100 v/v) was measured in the absence of additional calcium, with fibrin formation monitored visually. Encapsulation efficiency of thrombin was calculated by lysing purified liposomes with 0.1% Triton-X and measuring the thrombin activity using a fluorogenic substrate.
Loading platelets with liposomal thrombin
Purified liposomes were added to isolated platelets (1:100 v/v) and incubated at room temperature for 1 h with gentle agitation, in order for uptake to occur. The uptake of liposomes into platelets was confirmed as previously described [16] . To remove excess liposomes, platelets and liposomes were centrifuged at 250 9 g for 5 min and the supernatant was removed. Platelets were then washed twice in Tyrode's-HEPES buffer at 250 9 g for 5 min and resuspended either in Tyrode's-HEPES buffer or PPP as indicated.
Measuring platelet activation by flow cytometry
Platelets resuspended in Tyrode's-HEPES buffer (pH 7.4, unless otherwise indicated) were incubated with FR171113 (1 lM, Sigma) and ML354 (1 lM, Sigma) to inhibit PAR1 and PAR4, where applicable. Platelets were then activated with 0.5 lg mL À1 rat tail collagen (Sigma), stained with 10 ng lL À1 anti-human CD42b-FITC and 2 ng lL anti-human CD62P-APC antibodies (eBioscience, Waltham, MA, USA) and incubated at 37°C for 30 min. For flow cytometry analysis (FACSCalibur, BD Biosciences, Franklin Lakes, NJ, USA), platelets were identified using forward and side scatter, as well as positive FITC staining. Single-color controls were used to determine the background fluorescence of each stain and to define quadrants.
Measuring clot retraction in PRP
PRP (50 lL) was mixed into a total of 200 lL pH 7.4 Tyrode's-HEPES buffer with a final concentration of 3.75 mM CaCl 2 , and 10 lg mL À1 rat tail collagen or 120 pM recombinant tissue factor (Innovin, Dade Behring, Deerfield, IL, USA) as indicated. Samples were incubated at 37°C and images of the clots were obtained every 10 min. The total areas of the clot and the sample were measured using Quorum Analysis software.
Measuring thrombin generation in PRP
In the platelet inhibitor experiments, platelets were preincubated with either acetylsalicylic acid (ASA, 5 lg mL À1 ) or naproxen (5 lg mL À1 ) for 15 min at room temperature. In the trauma-patient plasma experiments, platelets were resuspended in PPP obtained from patients diagnosed with trauma-induced coagulopathy (TIC). Reconstituted PRP containing 10 lM of the fluorogenic substrate for thrombin was mixed 3:1 with 40 mM CaCl 2 , with a final concentration of 10 lM adenosine diphosphate (ADP; Sigma) where specified. Samples were incubated at 37°C and fluorescence (excitation, 360 nm; emission, 465 nm) was measured every 30 s using a plate reader (TECAN GENios Plus, Ma¨nnedorf, Switzerland). The lag time for thrombin generation was calculated by plotting the first derivative of the fluorescence readings over time.
Determining clot initiation and clot strength by thromboelastography
In whole blood experiments, washed platelets were resuspended in PPP and mixed 1:1 with red blood cells washed in phosphate buffered saline (PBS). In the acidosis experiments, reconstituted PRP was preincubated with hydrochloric acid (10 mM) for 15 min at room temperature, resulting in a plasma pH~7.2 to mimic mild acidosis. The pH of acidified plasma was determined using a plasma spectrophotometric assay with phenol red [23] . In the hemophilia A plasma experiments, platelets were resuspended in congenital FVIII-deficient PPP (HA-PRP; George King Bio-Medical, Inc., Overland Park, KS, USA) and clotting was initiated with 2 pM recombinant tissue factor. Reconstituted PRP or whole blood was mixed 3 : 1 with 40 mM CaCl 2 in a thromboelastography (TEG) cup and R time was measured at 37°C using a TEG Hemostasis Analyzer System 5000 (Haemonetics Corporation, Braintree, MA, USA).
Determining clot initiation and lysis by western blot
In the hemophilia A patient experiments, platelets were resuspended in congenital FVIII-deficient PPP. Reconstituted PRP (20 lL) was mixed into a total of 40 lL HEPESbuffered saline, with a final concentration of 10 mM CaCl 2 , 0.6 pM tissue factor and 1 nM tissue plasminogen activator (tPA), and incubated at 37°C. At specific time-points, the reaction was stopped with 100 lL of quench buffer (1 M DTT, 0.5 M EDTA, 8 M urea) and incubated at 60°C for 1 h to dissolve the clot. Samples were run on a 10% SDS-PAGE gel, transferred on to a nitrocellulose membrane, and probed using a fibrinogen antibody (1:50,000; Dako, Santa Clara, CA, USA) and a goat anti-rabbit secondary antibody (1:15,000; Abcam, Cambridge, UK).
Determining release of endogenous platelet FXIII
Platelets were resuspended in pH 7.4 Tyrode's-HEPES buffer and activated with 10 lg mL À1 rat tail collagen at 37°C for 30 min. Platelets were spun down at 250 9 g for 5 min to separate the platelet pellet from the releasate in the supernatant. Both pellet and supernatant samples were run on a 10% SDS-PAGE gel, transferred on to a nitrocellulose membrane, and probed using a FXIII antibody (1:1,000; Affinity Biologicals, Ancaster, Canada) and a rabbit anti-sheep antibody (1:10 000; Abcam).
Detecting fibrin formation and crosslinking
Platelets were resuspended in PPP and activated with 10 lg mL À1 rat tail collagen or 0.35 lM thrombin at 37°C for 30 min. Western blotting for fibrin(ogen) was carried out as described above.
Preparing fluorescent thrombin to measure uptake and release
Human alpha thrombin (1 mg) was fluorescently labeled using an Alexa Fluor 488 Protein Labeling Kit (Molecular Probes, Eugene, OR, USA), purified using a centrifugal filter with a 3-KDa cut-off (Millipore, Burlington, MA, USA), and resuspended in 50% glycerol (v/v). Fluorescent thrombin was loaded into liposomes and platelets as described above, visualized by running both pellet and supernatant samples on a 10% SDS-PAGE gel, and imaged with an Alexa 488 filter on a ChemiDoc Imaging System (Biorad, Hercules, CA, USA) using Image Lab software.
Results
Purification of liposomal thrombin
Unencapsulated thrombin was removed from the liposomal thrombin preparation using a cationic exchange column ( Figure S1A ). The column eluate did not induce platelet activation ( Figure S1B ). Purified liposomal thrombin did not initiate fibrin formation in plasma in the absence of calcium and did not change clot initiation time in recalcified plasma ( Figure S1C and S1D). The encapsulation efficiency of thrombin was 1.6%, producing a stock solution of approximately 70 nM liposomal thrombin, which was approximately 0.7 nM when added to platelets.
Susceptibility of platelets to collagen activation
To determine the effect of delivering liposomal thrombin to platelets, we first tested the sensitivity of normal (PLTs) and modified platelets (LT-PLTs) to activation by collagen, a subendothelial protein and platelet agonist that is exposed at sites of damaged vasculature [1] . Platelet activation was determined by measuring CD62P exposure using flow cytometry. Compared with PLTs, a higher percentage of LT-PLTs became activated when exposed to collagen (Fig. 1A) .
Collagen stimulation of LT-PLTs resulted in an additional 28 (AE 5)% activation compared with no agonist, whereas PLTs were only 11 (AE 3)% more activated after collagen stimulation. Without platelet agonists, LT-PLTs were 20 (AE 4)% activated, much higher than the 8.6 (AE 0.8)% activation for PLTs or the 7 (AE 0.03)% for platelets loaded with empty liposomes (EL-PLTs), and much lower than the 89 (AE 4)% activation for PLTs stimulated with unencapsulated thrombin (Fig. 1B) . Clot contraction was also accelerated with LT-PLTs (Fig. 1C) . Collagenstimulated clot contraction in PRP with LT-PLTs was approximately 2.2-fold faster than PLTs, and the final contracted clot was similar in size to those made using recombinant tissue factor (TF), a strong activator of clot formation and contraction [24] .
Effect of liposomal thrombin on clot initiation and clot strength
The lag time of thrombin generation in PRP was shorter with LT-PLTs, measured using a fluorogenic substrate, occurring at 5.1 (AE 0.1) min, compared with PLTs at 7.0 (AE 0.4) min ( Fig. 2A) . Platelets loaded with an inactivated form of thrombin (DFP-PLTs) that contained an irreversible active site inhibitor (diisopropylfluorophosphate-thrombin, DFP) had an endogenous thrombin generation lag time of 6.0 (AE 0.2) min. The enzymatic activity of DFP-inhibited thrombin was measured using a fluorogenic substrate of thrombin and had approximately 0.01% of the activity of uninhibited thrombin.
TEG was used to further characterize the clots formed by LT-PLTs compared with PLTs. The clot initiation time (R time) for PRP containing LT-PLTs (8.8 AE 1.7 min) was approximately 26% faster compared with PLTs (11.9 AE 2.5 min) (Fig. 2B) . In whole blood, the R time for LT-PLTs (11.2 AE 1.2 min) was approximately 13% faster ) in whole blood (Fig. 2C) . To characterize the effect of LT-PLTs on fibrin crosslinking and the susceptibility of fibrin to degradation, PRP clots with either PLTs or LT-PLTs were made in the presence of tPA. A western blot for fibrin(ogen) was used to monitor the a, b and c chains, as well as higher-molecular-weight bands corresponding to crosslinked fibrin and lower-molecular-weight bands corresponding to fibrin degradation products. The formation and degradation of high-molecular-weight bands were similar, but the b chain (~56 kDa) was stable for several hours longer in clots made with LT-PLTs compared with PLTs (Fig. 2D) .
Platelet response and clot formation during acidosis
More LT-PLTs responded to collagen activation compared with PLTs at pH levels ranging from 6.8 to 7.4 (Fig. 3A) , the range of blood pH that occurs during mild to severe acidosis [25] . To determine the effect of LTPLTs on clotting during acidosis, thrombin generation time was measured in acidified PRP (pH~7.2). On average, normal PRP (pH~7.4) had a thrombin generation time of 8.1 (AE 1.0) min. Acidifying PRP (pH~7.2) that contained PLTs slowed the generation of endogenous thrombin by 1.0 (AE 0.4) min (Fig. 3B) . In contrast, LTPLTs sped up thrombin generation time by 1.6 (AE 0.2) min in acidified PRP. TEG was used to confirm faster clot initiation, in which normal PRP at physiological pH had an R time of 8.5 (AE 1.4) min. Acidified PRP containing PLTs clotted approximately 10% slower compared with normal PRP, but acidified PRP containing LT-PLTs clotted approximately 10% faster compared with normal PRP (Fig. 3C ).
Clot formation with antiplatelet drugs
Normal PRP had an ADP-stimulated thrombin generation time of 7.2 (AE 0.7) min. This was 1.3 (AE 0.5) min slower in the presence of ASA or naproxen (Fig. 4A) . In contrast, PRP with LT-PLTs generated thrombin 0.4 (AE 0.4) and 0.6 (AE 0.4) min faster in the presence of ASA and naproxen compared with normal PRP, respectively.
Clot formation in plasma from patients with coagulopathies
HA-PRP is deficient in FVIII and has compromised thrombin generation [26, 27] . On average, normal PRP had an R time of 5.3 (AE 0.5) min, when clotting was initiated with TF and measured by TEG. R time for HA-PRP was 33 (AE 5)% slower compared with normal PRP, whereas HA-PRP with LT-PLTs was only 17 (AE 3)% slower compared with normal PRP (Fig. 4B) . In a western blot for fibrin(ogen), clots made with PLTs in the presence of tPA had faster b chain degradation when made with HA-PRP compared with normal plasma (Fig. 4C) . In contrast, the fibrin formed in clots of HA-PRP with LT-PLTs had a similar rate of degradation to clots made in normal PRP.
The effects of modified platelets in the plasma of patients with TIC was assessed by measuring the endogenous thrombin generation time. In two TIC patient samples, thrombin generation times were 5.0 (AE 0.1) and 6.7 (AE 0.2) min for PLTs. In both cases, adding LT-PLTs resulted in thrombin generation times of 3.9 (AE 0.1) and 5.9 (AE 0.1) min, respectively (Fig. 5) . Platelet uptake of liposomal thrombin and assessing interactions with substrates of thrombin Liposomal thrombin was internalized by 38 (AE 9.2)% of platelets, which decreased to 13 (AE 5.5)% with a general metabolic inhibitor (Fig. 6A) . Thrombin appeared to remain inside of platelets after they were activated by collagen, because fluorescent thrombin was detected inside platelets but not in the supernatant upon activation (Fig. 6B) . Cleavage of fibrinogen was not detected within the platelets or in the surrounding plasma when platelets were activated with collagen in the absence of calcium (Fig. 7A) .
Compared with PLTs, EL-PLTs and DFP-PLTs, only LTPLTs released endogenous platelet FXIII upon activation by collagen (Fig. 7B) . Inhibiting the platelet surface thrombin receptors PAR1 and PAR4 of LT-PLTs resulted in a similar level of collagen activation compared with uninhibited LT-PLTs (43.7% vs. 50.3%; Fig. 7C ).
Discussion
The results show that several aspects of coagulability of ex vivo transfusable platelets can be enhanced by loading them with an exogenous coagulation factor. Thrombin was encapsulated by passive loading into liposomes consisting of natural lipids and internalized by platelets isolated from fresh whole blood. It was important to minimize the extent to which platelets are activated prior to transfusion to minimize the risk of adverse events. The hemostatic potential of thrombin could be highly beneficial if transfused during bleeding, but unencapsulated thrombin would cause intense platelet activation and lead to thrombosis. Therefore, excess unencapsulated thrombin was removed using a cationic exchange column prior to incubation with platelets, resulting in no detectable thrombin activity in the eluate. The eluate did not cause platelet activation and purified liposomal thrombin did not cause fibrin formation in plasma or speed up calcium-induced clot initiation. Additionally, no enzymatically active thrombin was found outside of LT-PLTs before or after activation. Although incubating the platelets with liposomal thrombin increased the background activation from approximately 8.6% to 20%, it is well within the range of platelet activation considered safe for transfusions [28] .
The coagulability of LT-PLTs was improved in several ways. LT-PLTs were more sensitive and responsive to collagen activation compared with PLTs in several assays. LT-PLTs significantly decreased the clot initiation time and increased clot firmness in both PRP and whole blood. The fibrin formed in the presence of LT-PLTs was also less susceptible to lysis by tPA. To our knowledge, this is the first report of directly modifying platelets to enhance their coagulability. Direct modification of transfusable platelets may be useful in cases of acute bleeding, where a temporary increase in platelet coagulability may be desirable, whereas previous work in modifying precursor cells would permanently alter platelet function [14, 15] . Although the current approach would require much more development and testing before translation to clinical use, these proof-of-concept experiments suggest that increasing the coagulability of platelets without increasing their basal activation may have important implications for treating severe bleeding with platelet transfusions. This could be particularly important for cases of TIC, where damaged blood vessels cannot be efficiently sealed because of decreased platelet sensitivity to agonists, weaker clot formation and hyperfibrinolysis [5, 29] .
In a step towards determining the efficacy of LT-PLTs during severe bleeding, we tested LT-PLTs in several scenarios where platelet function and/or thrombin generation are compromised, using various combinations of the above assays. In all cases, endogenous thrombin generation was used as an indirect measure of the activation of the coagulation cascade, supplemented with other assays such as TEG and western blotting for fibrin to further characterize clot initiation, and aspects of mechanical strength and stability when applicable. Severe hemorrhage is often complicated by acidosis, which contributes to coagulopathy by impairing the activity of coagulation complexes such as FXa/Va, ultimately leading to decreased thrombin generation and prolonged clotting times [29] [30] [31] . In previous studies with animal models of acidosis, these coagulation defects were not reversed by correcting the pH back to physiological levels [32, 33] . Acetylsalicylic acid (ASA) and naproxen are irreversible antiplatelet drugs that can require platelet transfusions for emergency reversal during severe bleeding, although platelet transfusions are sometimes insufficient to restore hemostatic function [34] [35] [36] . Using LT-PLTs, we were able to overcome some of the coagulation defects caused by acidosis and antiplatelet drugs in vitro.
In order to determine the potential clinical relevance of platelets with enhanced coagulability, ex vivo clotting parameters, including thrombin generation time, clot initiation and clot strength, were measured in two different patient plasmas. Hemophilia A is a genetically acquired bleeding disorder resulting from FVIII deficiency [37] . Previously, platelet precursors were genetically modified to produce FVIII-expressing platelets, which were effective at treating several animal models of hemophilia A [14, 15] . In our experiments, LT-PLTs improved the clotting parameters in HA-PRP, which is likely to be a result of enhancing thrombin and fibrin generation. TIC is an example of acute severe bleeding that may benefit from LT-PLT transfusions, because it often presents with impaired platelet function, and transfusions of platelets or other blood components do not always correct coagulopathy [2, 3, 38] . In plasma samples collected from patients with TIC, LTPLTs sped up endogenous thrombin generation times. These experiments with patient plasma samples are proofof-concept experiments suggesting that enhancing platelet coagulability through increased platelet sensitivity to agonists and faster thrombin generation may be an effective strategy to overcome certain aspects of coagulopathies.
To identify the molecules that liposomal thrombin acted on, we analyzed several substrates of thrombin in platelets, including fibrinogen, FXIII, PAR1 and PAR4. Although we did not identify a specific substrate, the results provide several insights into the mechanism of action of LT-PLTs. Thrombin was internalized and appeared to remain inside the platelets because its release was not detected. Although the enzymatic activity of thrombin contributes to enhanced platelet coagulability, as demonstrated by several control experiments with DFP-inhibited thrombin, neither cleavage of FXIII nor fibrinogen was detected within platelets. This is especially interesting because FXIII is present primarily in the platelet cytoplasm [39] , and fibrinogen is found primarily in alpha granules [40] . This suggests that after internalization, exogenously delivered thrombin remains separated from both of these compartments. Inhibition of platelet thrombin receptors, PAR1 and PAR4, did not abrogate the increased sensitivity of LT-PLTs to collagen activation, suggesting that liposomal thrombin did not activate the receptors on the outer surface of the platelet. Platelet FXIIIA is normally externalized on the surface of activated platelets and contributes to clot contraction and thrombus stabilization [39] . The release of platelet FXIIIA by LT-PLTs may explain the decreased fibrinolysis and enhanced clot contraction, although it could also be a result of enhanced platelet activity and thrombin generation [41] [42] [43] . Either way, the exact mechanism by which the delivered thrombin leads to increased agonist responsiveness and FXIIIA release remains to be elucidated. Future studies on the mechanism of enhanced coagulability of LT-PLTs may determine the primary targets of exogenously delivered thrombin, as well as the intracellular location of the delivered thrombin.
Conclusions
These results demonstrate that thrombin can be encapsulated, delivered to and internalized by transfusable human platelets to enhance aspects of their coagulability ex vivo (Fig. 8 ). LT-PLTs had increased sensitivity and responsiveness to collagen, faster plasma thrombin generation times, faster clot initiation times and accelerated clot contraction, and contributed to anti-fibrinolysis. They also had minimally increased but statistically significant basal activation. LT-PLTs enhanced procoagulant activity in PRP under a wide range of coagulopathic conditions, including acidosis, antiplatelet drugs, hemophilia A and TIC. Future studies should test the safety and efficacy of transfusing LT-PLTs in animal models of severe acute hemorrhage. Overall, the results suggest that enhancing the coagulability of transfusable platelets, such as with the type of modification described here, may be a potential strategy to enhance hemostasis and aid in hemorrhage control.
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